Examination of IgM Rheumatoid Factor (IgM-RF) and Anti-cyclic Citrullinated Peptide Antibody (Anti-CCP Ab) in Japanese Patients with Palindromic Rheumatism

Mami Tamai¹, Atsushi Kawakami¹, Nozomi Iwanaga¹, Keita Fujikawa¹, Fumiko Tanaka¹, Toshiyuki Aramaki¹, Yasumori Izumi¹, Kouichiro Aratake¹, Kazuhiko Arima¹, Makoto Kamachi¹, Hideki Nakamura¹, Mingguo Huang¹, Hiroaki Ida¹, Tomoki Origuchi² and Katsumi Eguchi¹

Abstract

We have studied the serology of 6 patients with palindromic rheumatism. None of the patients fulfilled the classification criteria for rheumatoid arthritis at the entry; however, 4 out of the 6 patients were seropositive for IgM rheumatoid factor (IgM-RF) at entry. Sequential serological study was performed in 4 patients; IgM-RF changed from seronegative to seropositive in one patient, and the titer increased in another patient. Anti-cyclic citrullinated peptide antibody (anti-CCP Ab) at the entry was detected in only one of the 6 patients; that patient later developed RA. Although follow-up is necessary, the present study may suggest the importance of serological examination, especially anti-CCP Ab, in patients with palindromic rheumatism.

Key words: palindromic rheumatism, IgM-RF, anti-CCP Ab

Introduction

Palindromic rheumatism is characterized by recurrent attacks of acute arthritis of short duration. In the long term, some of these patients develop a connective tissue disease, usually rheumatoid arthritis (RA) (1, 2). Previous studies in Europe and North America showed that the presence of IgM rheumatoid factor (IgM-RF) in palindromic rheumatism patients indicates a future risk for RA (1-4), and anti-cyclic citrullinated peptide antibody (anti-CCP Ab) was recently reported in palindromic rheumatism patients (5). Thus, we measured IgM-RF and anti-CCP Ab in the sera of Japanese palindromic rheumatism patients.

Case Presentation

We encountered 6 patients with palindromic rheumatism, as diagnosed by the criteria described by Gonzalez-Lopez et al (1). Informed consent was obtained from all of the patients.

Table 1 summarizes the profiles of the 6 palindromic rheumatism patients. All patients were prospectively followed-up, and the disease duration was estimated from the time of first attack until the last consultation. Seroposivities of IgM-RF and anti-CCP Ab shown in Table 1, were obtained from the data of the latest serological examinations. Joint involvement in Table 1 shows the total joints affected during the follow-up period. Serology was serially examined in 4 patients; IgM-RF turned to be positive in one patient and its titer increased in one case (Fig. 1). Among the 6 patients, one patient developed RA later. IgM-RF was seropositive in 4 out of 6 patients; however, only the one patient who developed RA was positive for anti-CCP Ab. Anti-CCP Ab in this case was consistently positive; however, IgM-RF was negative during the follow-up period.
plain radiographs of the affected joints were examined serially (case 1 to case 6), but no erosive bone changes were not found in any of the patients (data not shown).

**Discussion**

Gonzalez-Lopez et al have reported that 28% of patients with palindromic rheumatism developed RA after a mean follow-up of 6 years (1). Previous investigations including that of Gonzalez-Lopez et al showed that seropositivity for IgM-RF could be one of the risk factors for subsequent development of RA (1-4). The present study includes 6 cases with a mean follow-up of 3.1 years. Among them, the one patient who developed RA later was seropositive for anti-CCP Ab and seronegative for IgM-RF. Thus, the presence of anti-CCP Ab might be a prognostic factor for future onset of RA. The involvement of proximal interphalangeal (PIP) joints, wrist joints and metacarpophalangeal (MCP) joints has been suggested to indicate future risk for RA in patients with palindromic rheumatism (1), and such involvement was observed in 5 out of 6 patients. Thus, further follow-up will be necessary to detect the onset of RA of our cases.

Van Gaalen et al recently revealed that the presence of anti-CCP Ab is the best predictor for the progression to RA in patients with undifferentiated arthritis (6). Anti-CCP Ab is reported to be found in 56.3% of patients with palindromic rheumatism in Spain (18 out of 32 patients); however, prediction of the future development of palindromic rheumatism to RA by anti-CCP Ab remains to be determined (5). Our prospective study of early-stage RA indicates that about 70% of the patients at baseline already show the seropositivity with anti-CCP Ab (7, 8); the difference in anti-CCP Ab seropositivity from that found by Salvador et al (5) in Spain may be due to arise from racial difference. Further study may answer question.

The present data are preliminary and limited; however, to our knowledge, this is the first prospective observation of Japanese patients with palindromic rheumatism regarding IgM-RF and anti-CCP Ab. Further clinical investigation, including a large number of patients will be necessary to clarify the significance of IgM-RF and anti-CCP Ab in the prediction of further onset of RA in Japanese palindromic rheumatism patients.

We thank Maiko Kubo, Nobuko Fukuda and Kouko Munechika for their technical assistance.

**Abbreviations:** ACR: American College of Rheumatology, anti-CCP Ab: anti-citrullinated peptide antibody, IgM-RF: IgM rheumatoid factor, MCP joint: metacarpophalangeal joint, MTP joint: metatarsophalangeal joint, PIP joint: proximal interphalangeal joint, RA: rheumatoid arthritis

**References**


© 2006 The Japanese Society of Internal Medicine
http://www.naika.or.jp/imindex.html